Plain-English translation of NCT06286878 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing a medication called in people who have just had a heart attack. The researchers want to see if this medication can help prevent dangerous blood clots and reduce damage to the heart. The study will compare people who take the medication to those who take a placebo (a pill with no active ingredient) to see which group does better.
Heart attacks are very serious, and one major risk after a heart attack is blood clots forming and causing another heart attack. Doctors already know this medication helps people with diabetes control their blood sugar, but they want to find out if it might also protect the heart by reducing blood clotting and preventing further damage.
You likely qualify if…
You likely don't qualify if…
You would take either the study medication or a placebo pill once daily by mouth while you are in the hospital after your heart attack. Doctors will check your blood platelets (clotting cells) within 48 hours of starting the medication, and you'll have follow-up blood tests and measurements at 30 days. The study will monitor your blood sugar levels, heart damage markers, kidney function, and inflammation to see how the medication affects your recovery.
AI-generated summary from trial data · Jun 2, 2026 · Not medical advice
Brazil